Forsta AP Fonden Reduces Holdings in AbbVie Inc. $ABBV

Forsta AP Fonden decreased its position in shares of AbbVie Inc. (NYSE:ABBV) by 2.8% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 428,762 shares of the company’s stock after selling 12,500 shares during the period. AbbVie makes up about 0.5% of Forsta AP Fonden’s investment portfolio, making the stock its 24th largest position. Forsta AP Fonden’s holdings in AbbVie were worth $79,587,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. KBC Group NV grew its holdings in AbbVie by 0.3% during the 2nd quarter. KBC Group NV now owns 1,107,709 shares of the company’s stock valued at $205,614,000 after purchasing an additional 3,589 shares during the last quarter. Jupiter Asset Management Ltd. lifted its stake in AbbVie by 171.4% in the second quarter. Jupiter Asset Management Ltd. now owns 293,098 shares of the company’s stock worth $54,405,000 after purchasing an additional 185,088 shares during the last quarter. SBI Securities Co. Ltd. boosted its position in shares of AbbVie by 1.7% during the second quarter. SBI Securities Co. Ltd. now owns 64,064 shares of the company’s stock valued at $11,892,000 after buying an additional 1,063 shares during the period. Ironwood Investment Counsel LLC boosted its position in shares of AbbVie by 20.4% during the second quarter. Ironwood Investment Counsel LLC now owns 11,970 shares of the company’s stock valued at $2,222,000 after buying an additional 2,030 shares during the period. Finally, National Pension Service grew its stake in shares of AbbVie by 5.8% during the second quarter. National Pension Service now owns 3,820,450 shares of the company’s stock valued at $709,152,000 after buying an additional 210,615 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on ABBV shares. Erste Group Bank lowered AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Citigroup reduced their target price on AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research note on Monday, November 3rd. JPMorgan Chase & Co. boosted their target price on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Wells Fargo & Company upped their price target on shares of AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. Finally, Hsbc Global Res lowered shares of AbbVie from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $236.57.

AbbVie Trading Up 2.9%

NYSE ABBV opened at $225.06 on Wednesday. AbbVie Inc. has a one year low of $163.81 and a one year high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The company has a market capitalization of $397.76 billion, a price-to-earnings ratio of 107.17, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The company’s 50-day simple moving average is $223.67 and its two-hundred day simple moving average is $203.22.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period last year, the firm earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a $1.73 dividend. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is 524.24%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.